RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Core Viewpoint - RedHill Biopharma has signed a Global Termination Agreement that enhances its cash position and eliminates previous encumbrances, allowing the company to focus on its R&D and commercial activities, marking a new chapter for the company [4][8]. Financial Impact - The Agreement resulted in RedHill receiving approximately $9.9 million in cash and gaining control over an additional $0.74 million, leading to a total increase of approximately $12.2 million in liabilities, but a net balance sheet reduction of about $2.3 million [4]. Business Operations - The Agreement ends all existing credit ties with the involved parties, removes the lien against Talicia®, and restores control over cash collections back to RedHill [4]. - RedHill is primarily focused on gastrointestinal and infectious diseases, promoting drugs such as Talicia® for H. pylori infection and Aemcolo® for travelers' diarrhea [8]. Development Programs - Key clinical late-stage development programs include: - Opaganib, targeting multiple indications with a collaboration for Acute Radiation Syndrome and a Phase 2/3 program for hospitalized COVID-19 [8]. - RHB-107, in late-stage development for non-hospitalized symptomatic COVID-19, with external funding covering its Phase 2 trial [8]. - RHB-102, RHB-104, and RHB-204, which are in various stages of development for gastrointestinal diseases and Crohn's disease [8].